from phenotypes observed in classical hereditary nonpolyposis colorectal cancer (HNPCC), which is caused by mutations in the MLH1 and MSH2 genes (Akiyama et al. 1997) . Generally, MSH6 families are characterized by later age of onset of the disease, and cancers of affected individuals exhibit low levels of instability mostly at mononucleotide repeats (Wijnen et al. 1999) .
Subjects and methods
The pedigree of the MSH6 family is presented in Fig. 1 . The proband (III-3), a 49-year-old woman with bilateral endometrioid ovarian cancer, had a positive family history of cancers. Her father died of colon cancer at the age of 83 years and her paternal grandmother died of endometrial cancer at the age of 69 years. Endometrial cancer was diagnosed at the age of 57 years in her cousin, who is at present 68 years old. Initial molecular analyses were performed on proband III-3. DNA was extracted from peripheral blood, and sequencing of all coding fragments of the MSH2 and MLH1 genes did not reveal mutation. The proband DNA was then analyzed for MSH6 changes.
In exon 5 of the MSH6 gene, we identified a frameshift mutation 3311-3312 delTT, which creates a termination codon at 1106 and removes the carboxy-terminal MSH2 interaction region and the nucleotide binding region (Guerrette et al. 1998 ).
Introduction
The MSH6 gene, along with MLH1, MSH2, PMS2, MLH3, and EXO1, belongs to a group of DNA mismatch repair genes, which, when mutated, cause development of inherited cancers mainly in the colon, rectum, and endometrium (Kurzawski et al. 2002; Debniak et al. 2000; Nicolaides et al. 1994; Wu et al. 2001a; Wu et al. 2001b; Akiyama et al. 1997) .
The MSH6 gene has been mapped on chromosome 2 (2p15-16) and is transcribed as a 4245-bp mRNA encoding a 153-kDa protein of 1360 amino acids. This MSH6 protein contains two domains that allow interaction with the MSH2 protein. Biochemical studies indicate that the MSH2-MSH6 complex recognizes base-base mispairs and small insertion-deletion loops (Guerrette et al. 1998; Acharya et al. 1996) .
Studies of affected individuals with MSH6 germline mutations indicate that the clinical phenotype is often different
The proband and family members were informed about the findings and were invited to be tested for the presence of the mutation. DNA testing for this mutation was performed in seven living relatives, three male relatives and five female relatives. Two relatives with a previously diagnosed HNPCC-related tumour (III-1, III-3) and one unaffected relative (IV-1) were carriers. Other relatives were negative for the MSH6 mutation (III-4, III-5, IV-4, IV-6, IV-7). The histopathological and clinical data of the proband were independently verified. Her current age is 63 years and she was diagnosed at age 49 years as having bilateral ovarian cancers of the endometrioid type with morphological malignancy grade G1/2 and clinical stage I/II, according to the International Federation of Gynecology and Obstetrics (FIGO).
Results and discussion
This case study of histologically verified ovarian cancers in an MSH6 carrier, as well as that previously reported (Wagner et al. 2001 ) are of endometrioid type. Thus, ovarian cancers of this type may be characteristic of MSH6 mutation carriers; such cancers have also been reported as characteristic in HNPCC cases (Watson et al. 2001) . A potential difference between such cancers in MLH1/MSH2 and MSH6 mutation carriers may be the age at diagnosis. The average age at diagnosis of ovarian cancers in MSH6 mutation carriers is 48 years, whereas these tumors in MSH2/MLH1 mutation carriers were diagnosed at an average age of 43 years.
Later age at diagnosis of cancers may be a major feature useful in differential diagnosis in MSH2/MLH1 and MSH6 families because colorectal and endometrial cancers also occur at a later age in MSH6 mutation carriers: 53 vs 43 years and 55 vs 48.5 years, respectively. In approximately 20% of families with the MSH6 mutation, cancers appear at Ն50 years of age, despite the fact that MSH6 mutation analyses were performed frequently, if not consecutively, in those cases that showed Amsterdam criteria and were negative for MSH2/MLH1 (Akiyama et al. 1997; Wu et al. 1999; Wagner et al. 2001; Wijnen et al. 1999; Kolodner et al. 1999; Miyaki et al. 1997; Plaschke et al. 2000; Huang et al. 2001; Berends et al. 2002; Plaschke et al. 2002; Verma et al. 1999) .
In summary, it may be worthwhile to develop studies to assess whether later onset of endometrioid ovarian cancer is characteristic of carriers with MSH6 constitutional mutations. Fig. 1 . Pedigree of the MSH6 family. E, Endometrial cancer; R, rectal cancer; Ov, ovarian cancer; Liv, liver cancer. The numbers following abbreviations indicate the age at diagnosis; (ϩ), MSH6-mutation positive; (Ϫ), MSH6-mutation negative. Arrow indicates the proband
